USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name:
AVAXIA BIOLOGICS, INC.
Address:
128 Spring Street
Suite 620
Lexington, MA
Phone:
N/A
URL:
N/A
EIN:
161172596
DUNS:
611725966
Number of Employees:
N/A
Woman-Owned?:
No
Minority-Owned?:
No
HUBZone-Owned?:
No

Commercialization:

Has been acquired/merged with?:
N/A
Has had Spin-off?:
N/A
Has Had IPO?:
N/A
Year of IPO:
N/A
Has Patents?:
N/A
Number of Patents:
N/A
Total Sales to Date $:
$ 0.00
Total Investment to Date $
$ 0.00
POC Title:
N/A
POC Name:
N/A
POC Phone:
N/A
POC Email:
N/A
Narrative:
N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $513,539.00 4
SBIR Phase II $1,538,055.00 1

Award List:

DEVELOPMENT AND BACTERIOLOGICAL STUDIES OF THE SNAP CAP

Award Year / Program / Phase:
1991 / SBIR / Phase I
Award Amount:
$29,402.00
Agency:
HHS
Principal Investigator:
Gibson, Roger M , Principal Investigator
Abstract:
The problem to be addressed involves a well documented concern in the field of intravenous therapy and invasive hemodynamic monitoring. fluid filled catheters, while infusing fluids into the blood vessels, can carry bacteria into a patient's blood, leading to nosocomial bacteremias. the part of the… More

Topical Anti-TNF Antibody for Oral Mucositis

Award Year / Program / Phase:
2009 / SBIR / Phase I
Award Amount:
$125,242.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): To develop an effective drug for oral mucositis Background: Oral mucositis is a painful dose-limiting side effect of many forms of cancer radiation and chemotherapy. According to a recent report by the National Comprehe nsive Cancer Network, mucositis is the most… More

Oral anti-TNF antibody for inflammatory bowel disease

Award Year / Program / Phase:
2010 / SBIR / Phase I
Award Amount:
$213,589.00
Agency:
HHS
Principal Investigator:
Abstract:
DESCRIPTION (provided by applicant): Project Summary Long Term Goal: To develop a drug for treating inflammatory bowel disease with reduced side effects Background: Inflammatory bowel disease (IBD) is a chronic inflammatory disorder of the gastrointestinal tract. There are two types of inflammatory… More

Oral Antibody Therapy for Celiac Disease

Award Year / Program / Phase:
2011 / SBIR / Phase I
Award Amount:
$145,306.00
Agency:
HHS
Principal Investigator:
Barbara S. Fox – 508-259-5929
Abstract:
DESCRIPTION (provided by applicant): Celiac disease is a common and debilitating gastrointestinal disorder. It is caused by an inappropriate immunological response to gluten. Although celiac disease can usually be controlled by strict avoidance of gluten in the diet, the ubiquity of gluten in the… More

Oral anti-TNF antibody for inflammatory bowel disease

Award Year / Program / Phase:
2012 / SBIR / Phase II
Award Amount:
$1,538,055.00
Agency:
HHS
Principal Investigator:
Daniel E. Tracey – 508-259-5929
Abstract:
DESCRIPTION (provided by applicant): To develop an oral anti-TNF antibody therapeutic that is safe and effective enough to be used as a first line therapy for inflammatory bowel disease. Problem: Inflammatory bowel disease (IBD) comprises two chronic inflammatory disorders of the gastrointestinal… More